Study of Efbemalenograstim alfa for ovarian or cervical cancer chemotherapy
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a medication (Efbemalenograstim alfa) that helps boost your white blood cell counts during chemotherapy for ovarian or cervical cancer. It aims to reduce the risk of serious infections (febrile neutropenia) while you receive standard treatment with paclitaxel plus carboplatin or cisplatin, with or without bevacizumab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have ovarian cancer (including fallopian tube or primary peritoneal), or cervical cancer that is either newly diagnosed or has returned/spread.
- You are scheduled to receive 3 to 6 cycles of chemotherapy with paclitaxel and carboplatin or cisplatin (with or without bevacizumab).
- You have at least one factor that raises your risk of developing a fever from low white blood cells (like being over 65 on full-dose chemo, having had chemo or radiation before, or having poor nutrition).
- Your blood counts (especially white cells, hemoglobin, and platelets) are at a safe level before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
This trial is testing a new drug, LBL-024, combined with chemotherapy (with or without a targeted therapy called bevacizumab) for ovarian cancer that has stopped responding to standard platinum-based treatment. The goal is to see if this combination can effectively shrink tumors and slow the disease's progression.
This trial tests a new combination of treatments for advanced ovarian, fallopian tube, or peritoneal cancer. It combines chemotherapy and immunotherapy (drugs that help your immune system fight cancer) with a special vaccine made from your own tumor. The goal is to see if this approach is more effective than standard treatment.
This trial tests if a drug called Efbemalenograstim Alfa can help prevent a serious drop in white blood cells (febrile neutropenia) during chemotherapy. It is for patients with solid tumors who have a high or intermediate risk of this condition.
This trial tests a medication that aims to reduce the risk of dangerously low white blood cell counts (neutropenia) after chemotherapy combined with immunotherapy for certain advanced lung or esophageal cancers. It may help prevent infections and other complications, making treatment safer.
This Phase 2 trial compares two different treatment strategies as the first chemotherapy after surgery for advanced epithelial ovarian, peritoneal, or fallopian-tube cancer. It may help doctors find a more effective or better-tolerated approach for people in your situation.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.